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Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterised by progressive
muscular paralysis reflecting degeneration of motor neurones in the primary motor cortex,
corticospinal tracts, brainstem and spinal cord. Incidence (average 1.89 per 100,000/year) and
prevalence (average 5.2 per100,000) are relatively uniform in Western countries, although foci of
higher frequency occur in the Western Pacific. The mean age of onset for sporadic ALS is about 60
years. Overall, there is a slight male prevalence (M:F ratio~1.5:1). Approximately two thirds of
patients with typical ALS have a spinal form of the disease (limb onset) and present with symptoms
related to focal muscle weakness and wasting, where the symptoms may start either distally or
proximally in the upper and lower limbs. Gradually, spasticity may develop in the weakened
atrophic limbs, affecting manual dexterity and gait. Patients with bulbar onset ALS usually present
with dysarthria and dysphagia for solid or liquids, and limbs symptoms can develop almost
simultaneously with bulbar symptoms, and in the vast majority of cases will occur within 1–2 years.
Paralysis is progressive and leads to death due to respiratory failure within 2–3 years for bulbar
onset cases and 3–5 years for limb onset ALS cases. Most ALS cases are sporadic but 5–10% of
cases are familial, and of these 20% have a mutation of the SOD1 gene and about 2–5% have
mutations of the TARDBP (TDP-43) gene. Two percent of apparently sporadic patients have SOD1
mutations, and TARDBP mutations also occur in sporadic cases. The diagnosis is based on clinical
history, examination, electromyography, and exclusion of 'ALS-mimics' (e.g. cervical spondylotic
myelopathies, multifocal motor neuropathy, Kennedy's disease) by appropriate investigations. The
pathological hallmarks comprise loss of motor neurones with intraneuronal ubiquitin-
immunoreactive inclusions in upper motor neurones and TDP-43 immunoreactive inclusions in
degenerating lower motor neurones. Signs of upper motor neurone and lower motor neurone
damage not explained by any other disease process are suggestive of ALS. The management of ALS
is supportive, palliative, and multidisciplinary. Non-invasive ventilation prolongs survival and
improves quality of life. Riluzole is the only drug that has been shown to extend survival.
Disease names
Amyotrophic lateral sclerosis (ALS), Motor neurone dis-
ease (MND), Charcot's disease, Lou Gehrig's disease
Included diseases
Amyotrophic lateral sclerosis (ALS) is a term used to cover
the spectrum of neurodegenerative syndromes character-
Published: 3 February 2009
Orphanet Journal of Rare Diseases 2009, 4:3 doi:10.1186/1750-1172-4-3
Received: 22 October 2008
Accepted: 3 February 2009
This article is available from: http://www.ojrd.com/content/4/1/3
© 2009 Wijesekera and Leigh; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Orphanet Journal of Rare Diseases 2009, 4:3 http://www.ojrd.com/content/4/1/3
Page 2 of 22
(page number not for citation purposes)
ised by progressive degeneration of motor neurones.
However, it is also the term used in modern clinical prac-
tice to indicate the commonest form of the disease, Clas-
sical (Charcot's) ALS. Other syndromes related to this
spectrum of disorders include, Progressive bulbar palsy
(PBP), Progressive muscular atrophy (PMA), Primary lat-
eral sclerosis (PLS), Flail arm syndrome (Vulpian-Bern-
hardt syndrome), Flail leg syndrome (Pseudopolyneuritic
form) and ALS with multi-system involvement (e.g., ALS-
Dementia). Lord Russell Brain proposed the term Motor
neurone disease (MND) to incorporate these conditions
into a single spectrum of disorders [1]. The terms 'bulbar
onset ALS' and 'spinal onset ALS' have largely replaced the
terms PBP and Charcot's ALS in current practice. These
syndromes share a common molecular and cellular
pathology comprising of motor neurone degeneration
and the presence of characteristic ubiquitin-immunoreac-
tive (Ub-IR) and TDP-43 immunoreactive (TDP43-IR)
intraneuronal inclusions, as described later [2-4].
Another group of neurodegenerative motor neurone dis-
orders referred to as adult-onset spinal muscular atrophies
(e.g., Kennedy's syndrome) which, while affecting ante-
rior horn cells of the spinal cord and/or brainstem, are not
considered in this article as they have a distinct molecular
pathology unrelated to ALS, and have a more benign dis-
ease course.
Definition and diagnostic/classification criteria
ALS can be defined as a neurodegenerative disorder char-
acterised by progressive muscular paralysis reflecting
degeneration of motor neurones in the primary motor
cortex, brainstem and spinal cord. "Amyotrophy" refers to
the atrophy of muscle fibres, which are denervated as their
corresponding anterior horn cells degenerate, leading to
weakness of affected muscles and visible fasciculations.
"Lateral sclerosis" refers to hardening of the anterior and
lateral corticospinal tracts as motor neurons in these areas
degenerate and are replaced by gliosis [5].
Despite advances in investigative medicine over the past
century, the diagnosis of ALS is based on the presence of
very characteristic clinical findings in conjunction with
investigations to exclude "ALS-mimic" syndromes (e.g.
Cervical radiculomyelopathy). The latter conditions lead
to diagnostic error in 5–10% of cases [6,7]. The clinical
finding of signs suggestive of combined upper motor neu-
rone (UMN) and lower motor neurone (LMN) that can-
not be explained by any other disease process (evident on
electrophysiological, imaging, cerebrospinal fluid (CSF)
or serological studies), together with progression compat-
ible with a neurodegenerative disorder, is suggestive of
ALS. Thus, investigation results alone (e.g., evidence of
chronic denervation on electromyography (EMG)) are
not adequate for achieving a diagnosis, and must be inter-
preted in light of the patient's history and clinical find-
ings.
The World Federation of Neurology (WFN) Research
Group on Motor Neuron Diseases have developed the
1994 'El Escorial' diagnostic criteria [8] and the revised
2000 'Airlie House' criteria [9] to aid in diagnosing and
classifying patients for research studies and drug trials.
The revised Airlie House criteria are shown in Table 1, and
based on these criteria patients can be classified into 'Clin-
ically definite', 'Clinically probable', 'Clinically probable-
Laboratory supported' and 'Clinically possible' categories.
In the previous 1994 classification, patients with a pure
LMN syndrome were classified into the 'Clinically sus-
pected' category, which was removed from the revised cri-
teria. However, it is well recognised that a significant
number of patients who either have a pure LMN syn-
drome or who early in the course of the disease do not
have obvious UMN signs, will undoubtedly have ALS (or
a variant) but will not fall into these categories in the
revised criteria. Therefore, these criteria are probably more
useful for research purposes and therapeutic trials, rather
than day-to-day clinical practice. A recent rationalisation
of the El Escorial Criteria (the Awaji consensus, see below)
[10] simplifies the criteria and in our opinion should be
adopted.
Epidemiology
The incidence of sporadic amyotrophic lateral sclerosis
(SALS) in the 1990's is reported to be between 1.5 and 2.7
per 100,000 population/year (average 1.89 per 100,000/
year) in Europe and North America [11], with a uniform
incidence across these countries. The point prevalence in
the 1990's ranges from 2.7 to 7.4 per 100,000 (average 5.2
per 100,000) in western countries [11]. The lifetime risk
of SALS by the age of 70 has been estimated at 1 in 1,000
[12,13] but a more accurate estimate is more likely to be
1 in 400 [14,15]. A consistent finding in studies is that
there is a slight excess of males are affected more than
females, with a M:F ratio about 1.5:1, although more
recent data suggests that the gender ratio may be
approaching equality [11,16-18]. Explanations for this
male excess have been attributed to possible protective
hormonal factors in women, increased likelihood of
males being exposed to putative risk factors and under
ascertainment of elderly women in some population reg-
isters [19,20]. A review published in 2001 found the mor-
tality rates of ALS in the 1990's ranged from 1.54 to 2.55
per 100,000/year and a more recent study estimated the
figure to be 1.84 per 100,000 persons in the US popula-
tion [11,21]. The mean age of onset for sporadic ALS
(SALS) varies between 55–65 years with a median age of
onset of 64 years[22,23]. Only 5% of cases have an onset
before the age of 30 years [23], although juvenile sporadic
onset cases are being increasingly recognised [24]. BulbarOrphanet Journal of Rare Diseases 2009, 4:3 http://www.ojrd.com/content/4/1/3
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onset is commoner in women and in older age groups,
with 43% of patients over the age of 70 presenting with
bulbar symptoms compared to 15% below the age of 30
[23,25,26].
Although most cases of ALS are sporadic, about 5% of
cases have a family history of ALS (Familial ALS; FALS)
[27]. There is an often Mendelian inheritance and high
penetrance, with most cases having autosomal dominant
pattern of inheritance, although autosomal recessive ped-
igrees have been reported [28,29]. The ages of onset of
FALS is about a decade earlier than for sporadic cases,
affects males and female equally, and have a shorter sur-
vival [28,30,31]. Age of onset in FALS has a normal Gaus-
sian distribution, whereas SALS has an age dependant
incidence [32]. Juvenile onset ALS (jALS) is a term used
when age of onset is less than 25 years [33]. Most cases are
autosomal recessive although dominant inheritance
linked to chromosome 9q34 (ALS4, senataxin) has been
reported [34]. Recessive forms have been mapped to chro-
mosome regions 2q33 (ALS2, alsin), and 15q12-21
[35,36].
Geographic loci of the Western Pacific form of ALS, where
the prevalence is 50–100 times higher than elsewhere
world have been reported, although the cause of these
aggregations remains elusive [37]. These populations
include the Chamorro people of Guam and Marianas
island, the Kii peninsula of Honshu Island, and the Auyu
and Jakai people of south west New Guinea, in whom ALS
is associated with the Parkinsonism and dementia (ALS-
PD complex) [38,39]. More recent studies however have
shown a decrease in incidence of both ALS and PDC in
these areas over the past 40 years, although the incidence
of PDC slightly increased during the eighties and nineties
[37,40-42].
Clinical features
The features of ALS were first clearly described as a clinico-
pathological entity by Jean Martin Charcot in 1869 and in
subsequent articles in 1874 [43,44]. However, before that
Bell (1824), Aran (1850), Duchenne (1851), and Cruveil-
her (1853) made important observations that contributed
to the understanding of the clinical and pathological syn-
drome [45-50].
Approximately two thirds of patients with typical ALS
have a spinal form of the disease (classical 'Charcot ALS').
They present with symptoms related to focal muscle weak-
ness where the symptoms may start either distally or prox-
imally in the upper limbs and lower limbs. Rarely,
patients may notice focal muscle wasting before onset of
weakness, and some patients may present with a spastic
paraparesis. Patients may have noticed fasciculations
(noticed as involuntary muscle twitching) or cramps pre-
ceding the onset of weakness or wasting for some months
Table 1: Summary of Revised El Escorial Research Diagnostic Criteria for ALS (Brooks et al., 2000)
The diagnosis of ALS requires:
1 Evidence of LMN degeneration by clinical, electrophysiological or neuropathological examination;
2 Evidence of UMN degeneration by clinical examination, and
3 Progressive spread of symptoms or signs within a region or to other regions, as determined by history or examination,
Together with the absence of:
[1] Electrophysiological and pathological evidence of other disease that might explain the signs of LMN and/or UMN degeneration, and
[2] Neuroimaging evidence of other disease processes that might explain the observed clinical and electrophysiological signs
Categories of clinical diagnostic certainty on clinical criteria alone
Definite ALS
￿ UMN signs and LMN signs in 3 regions
Probable ALS
￿ UMN signs and LMN signs in 2 regions with at least some UMN signs rostral to LMN signs
Probable ALS – Laboratory supported
￿ UMN signs in 1 or more regions and LMN signs defined by EMG in at least 2 regions
Possible ALS
￿ UMN signs and LMN signs in 1 region (together), or
￿ UMN signs in 2 or more regions
￿ UMN and LMN signs in 2 regions with no UMN signs rostral to LMN signs
UMN signs: clonus, Babinski sign, absent abdominal skin reflexes, hypertonia, loss of dexterity.
LMN signs: atrophy, weakness. If only fasciculation: search with EMG for active denervation.
Regions reflect neuronal pools: bulbar, cervical, thoracic and lumbosacral.Orphanet Journal of Rare Diseases 2009, 4:3 http://www.ojrd.com/content/4/1/3
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(or years), but rarely are these the presenting symptoms.
The weakness is usually of insidious onset, and patients
may notice that symptoms are exacerbated by cold
weather. Although it is usually asymmetrical at onset, the
other limbs develop weakness and wasting sooner or later,
and most patients go on to develop bulbar symptoms and
eventually respiratory symptoms (although not necessar-
ily in that sequence). Gradually, spasticity may develop in
the weakened atrophic limbs, affecting manual dexterity
and gait. During late stages of the disease patients may
develop 'flexor spasms', which are involuntary spasms
occurring due to excess activation of the flexor arc in a
spastic limb. Occasionally encountered symptoms
include new bladder dysfunction (such as urgency of mic-
turition), sensory symptoms, cognitive symptoms and
multi-system involvement (e.g. dementia, parkinsonism).
Patients with bulbar onset ALS usually present with dysar-
thria of speech, which may initially only be apparent after
ingestion of small amount of alcohol. Rarely, patients
may present with dysphagia for solid or liquids before
noticing speech disturbances. Limbs symptoms can
develop almost simultaneously with bulbar symptoms
and in the vast majority of cases will occur within 1–2
years. Almost all patients with bulbar symptoms develop
sialorrhoea (excessive drooling) due to difficulty swallow-
ing saliva and mild UMN type bilateral facial weakness
which affects the lower part of the face. 'Pseudobulbar'
symptoms such as emotional lability and excessive yawn-
ing are seen in a significant number of cases.
About 5% of cases with ALS present with respiratory weak-
ness without significant limb or bulbar symptoms
[51,52]. These patients present with symptoms of type 2
respiratory failure or nocturnal hypoventilation such as
dyspnoea, orthopnoea, disturbed sleep, morning head-
aches, excessive day time somnolence, anorexia,
decreased concentration and irritability or mood changes
[53].
The examination early in the course of limb onset disease
usually reveals focal muscle atrophy especially involving
the muscles of the hands, forearms or shoulders in the
upper limbs, and proximal thigh or distal foot muscle in
the lower limbs. Fasciculations are usually visible in more
than one muscle group. Spasticity is evident in the upper
limbs by increased tone and a supinator 'catch', and in the
lower limbs with a patellar 'catch' and clonus together
with hypertonia. Tendon reflexes are pathologically brisk
in a symmetrical manner, including the finger jerks in the
upper limbs and positive crossed adductor reflex in the
lower limbs. Abnormal spread of tendon reflexes beyond
the stimulated muscle group may be evident. The Hoff-
mann's sign may be positive in the upper limbs and
plantar response is often extensor. In patients with bulbar
dysfunction, dysarthria may arise from either LMN
pathology or pseudobulbar palsy from UMN disorder,
leading to slow slurred speech or a nasal quality. On
examining the cranial nerves, the jaw jerk may be brisk,
especially in bulbar-onset disease. An upper motor neu-
rone type facial weakness affects the lower half of the face
causing difficulty with lip seal and blowing cheeks, but
often varying degrees of UMN and LMN facial weakness
coexist. The gag reflex is preserved and is often brisk while
the soft palate may be weak. Patients develop fascicula-
tions and wasting of the tongue, and tongue movements
are slowed due to spasticity. The rest of the cranial nerves
remain intact, although in late stages of the disease
patients may very rarely develop a supranuclear gaze palsy
[54,55]. Sensory examination is almost always unremark-
able. As disease progresses, patients develop the character-
istic picture of the combination of upper motor neurone
and lower motor neurone signs coexisting within the
same central nervous system region, affecting the bulbar,
cervical, thoracic and lumbar territories. Respiratory fail-
ure and other pulmonary complications are the usual
cause of death in ALS. However, patients who are kept
alive by tracheostomy assisted ventilation are found to
eventually develop a profound state motor paralysis
termed the 'totally locked-in state' (TLS), were there is
paralysis of all voluntary muscles and varying degrees of
oculomotor impairment [56,57].
Clinical features of variant disorders
Variants of MND have differing clinical presentations, rate
of progression and prognosis. Opinion is divided as to
whether these syndromes should be classed as separate
entities from ALS, although there is evidence that the may
be a common molecular pathology.
The syndrome of progressive muscular atrophy (PMA)
accounts for 5–10% of patients with MND, and indicates
a pure lower motor neurone syndrome without accompa-
nying upper motor neurone signs [58]. It is almost always
of limb onset, but patients may eventually develop swal-
lowing difficulties. It is reported that up to 50% of
patients may develop UMN signs and go on to develop
typical ALS picture [59].
The "flail arm" and "flail leg" variants are initially local-
ised forms with a predominantly lower motor neuron
presentation. In the flail arm variant (which also is known
as the Vulpian-Bernhardt syndrome [60] and Brachial
amyotrophic diplegia [61]), weakness and wasting pre-
dominantly affects the proximal upper limb in a symmet-
rical pattern, leading to severe wasting around the
shoulder girdle and the arms hanging flaccidly either side.
Typically, the tendon reflexes in the upper limbs are
depressed or absent, but patients may have retained
reflexes or focal brisk reflexes especially in the unaffectedOrphanet Journal of Rare Diseases 2009, 4:3 http://www.ojrd.com/content/4/1/3
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limb when the disease is asymmetrical at the onset. The
lower limbs remain strong for some years but eventually
spasticity and wasting develops. Swallowing difficulties
and diaphragmatic weakness are usually late features
[62,63]. In the flail leg syndrome (also known as the Pseu-
dopolyneuritic form of ALS) [64], weakness and wasting
begins in the distal lower limbs affecting both lower limbs
in a symmetrical manner. Again the clinical features are of
a lower motor neurone syndrome with hypotonia and
depressed tendon reflexes. Pyramidal signs are usually
absent, although it is not unusual for these patients to
have focal brisk reflexes in the unaffected limb when the
disease is asymmetrical [65]. The unusual clinical picture
together with lack of neurophysiological evidence of den-
ervation in other regions can lead to considerable diag-
nostic delays. These two variants characteristically show
slower progression compared to more typical forms of
ALS [61,62,66-68].
Primary lateral sclerosis is a clinically progressive pure
upper motor syndrome that cannot be attributed to
another disease process. There is ongoing debate as to
whether this syndrome is in fact an entirely separate dis-
order to ALS, but there is evidence from pathological stud-
ies that hallmarks of ALS such as ubiquitinated inclusions
are present in this condition. Patients present with a pure
upper motor neurone syndrome with either absent or
minimal lower motor neurone signs. It can be difficult to
differentiate PLS from ALS during the early stages as some
patients with typical ALS may only manifest UMN signs.
For this reason, some authors have suggested that LMN
signs must be absent for 3 years from onset to confidently
diagnose PLS [69]. However, there may be electrophysio-
logical evidence of LMN involvement in PLS patients
despite the absence of clinical LMN signs, and some
patients may develop wasting of small muscles of the
hands, adding to the diagnostic confusion [70,71], a con-
dition called by some authors as "UMN-dominant ALS"
[72,73]. Prognosis for PLS is considerably better than for
typical ALS [72].
It is recognised that patients with ALS may exhibit a range
of cognitive abnormalities ranging from impaired frontal
executive dysfunction in 20–40% of patients, to overt
fronto-temporal dementia (FTLD) in approximately 5%
of cases [74]. Cognitive abnormalities may precede or
occur after the onset of motor symptoms. Neuropatholog-
ical and neuroimaging studies have indicated that this
subset of patients with ALS-dementia may represent a part
of spectrum between patients with pure FTLD and ALS
[75,76].
Aetiology
The cause of ALS/MND is unknown although some
genetic risk factors have been identified. Recent reviews
on the role of environmental risk factors in the causation
of ALS have concluded that there is no consistent associa-
tion between a single environmental factor and risk of
developing ALS. Most authors favour a hypothesis of com-
plex genetic-environmental interaction as the causal fac-
tor for motor neuron degeneration [77,78].
Putative exogenous risk factors associated with develop-
ment of ALS investigated in case-control studies have been
reviewed, and are summarised in Appendix 1 [19,39]. By
applying an evidenced based approach, it was found that
only smoking is likely to be associated with developing
ALS, while other risk factors were weakly related. More
recent case-control studies have estimated the relative risk
(RR) of ALS of 0.8–1.67 in smokers compared to non-
smokers [79,80], and an odds ratio (OR) of 1.6 independ-
ent of age, level of education and occupation [81].
Pathogenesis of motor neurone degeneration in 
ALS
The exact molecular pathway causing motor neurone
degeneration in ALS is unknown, but as with other neuro-
degenerative diseases, is likely to be a complex interplay
between multiple pathogenic cellular mechanisms which
may not be mutually exclusive [77,78]. These include:
1. Genetic factors
20% of cases with autosomal dominant FALS and 2% of
patients with SALS show mutations in the Copper-Zinc
superoxide dismutase (SOD1) gene [82]. Mutations in the
gene are though to cause disease through a toxic gain of
function rather than causing impairment of the antioxi-
dant function of the SOD1 enzyme [77]. Other genes
causing familial MND include alsin (ALS2) [83,84], sena-
taxin (ALS4) [85], Vesicle associated membrane protein
(VAPB, ALS8) [86], Angiogenin [87,88] and a mutation in
the p150 subunit of dynactin (DCTN1) [89,90]. Recently,
mutations in TARDBP gene (encoding the TAR-DNA bind-
ing protein TDP-43) located on chromosome 1p36.22
have been linked to familial and sporadic ALS [91-93].
Several other gene mutations have been identified in spo-
radic cases which may increase susceptibility to ALS, such
as mutations in the KSP repeat region in the NEFH gene
(encoding neurofilament heavy subunit) [94,95], apoli-
poprotein E ∑4 genotype (APOE) [96], decreased expres-
sion of EAAT2 protein [97,98] and alterations in the
Vascular endothelial growth factor (VEGF) gene [99] to
name a few (See Table 2).
2. Excitotoxicity
This is the term for neuronal injury induced by excessive
glutamate induced stimulation of the postsynaptic gluta-
mate receptors such as cell surface NMDA receptors and
AMPA receptors [77,100]. This over stimulation of gluta-
mate receptors is thought to result in massive calciumOrphanet Journal of Rare Diseases 2009, 4:3 http://www.ojrd.com/content/4/1/3
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influx into the neurons, leading to increased nitric oxide
formation and thereby neuronal death. Glutamate levels
in CSF are elevated in some patients with ALS [101,102].
This elevation has been attributed to the loss of the glial
cell excitatory amino acid transporter EAAT2 [103].
3. Oxidative stress
Oxidative stress has longed been linked to neurodegener-
ation and it is known that accumulation of reactive oxy-
gen species (ROS) cause cell death. As mutations in the
anti-oxidant enzyme superoxide dismutase 1 (SOD1)
gene can cause familial ALS, there is significant interest in
this mechanism underlying neurodegenerative process in
ALS. This hypothesis is supported by the finding of bio-
chemical changes reflecting free radical damage and
abnormal free radical metabolism in CSF and post mor-
tem tissue samples of ALS patients [104-107]. In addition,
fibroblasts cultured from ALS patients shows increased
sensitivity to oxidative damage controls [108].
4. Mitochondrial dysfunction
Abnormalities in mitochondrial morphology and bio-
chemistry have been reported in sporadic ALS patients,
SOD1 transgenic mice and cellular models [109-115].
Mitochondria from ALS patients show elevated calcium
levels and decreased activity of respiratory chain com-
plexes I and IV, implicating defective energy metabolism
[112,116]. Mitochondrial DNA mutations have been
described in ALS patients [117-119].
5. Impaired axonal transport
Motor neuron axons may reach up to one metre in length
in humans, and rely on efficient intracellular transport
systems. These systems consist of anterograde (slow and
fast) and retrograde transport systems, and rely on molec-
ular 'motors', the kinesin complex of proteins (for antero-
grade) and the dynein-dynactin complex (for retrograde)
[120]. SOD1 transgenic mouse models of ALS show evi-
dence of slowed anterograde transport and retrograde
transport [121-124]. Although no such findings have
been observed in humans with ALS, mutations in the
kinesin genes are known to cause neurodegenerative
motor nerve diseases in humans such as hereditary spastic
paraplegia and Type 2A Charcot-Marie-Tooth disease
[125,126]. Mutations in the dynactin complex cause a
Table 2: Familial ALS (fALS) gene mutations and clinical features
Familial ALS type Locus (gene address) Gene Inheritance Clinical pattern Mutations Causes sporadic disease
ALS1 21q SOD1 AD Classical > 120 yes
ALS2 2q33 ALSIN AR Young onset, UMN 10 no
ALS3 18q21 AD Classical not known not known
ALS4 9q34 SETX AD Young onset, slow 3 Probably not
ALS5 15q15 not known AR Young onset not known Probably not
ALS6 16q21 not known AD Classical not known not known
ALS7 20ptel-p13 not known AD Classical not known not known
ALS8 20q13.3 VAPB AD Varied 1 no
ALS-FTD 9q21-q22 not known AD With FTD not known not known
ALS-FTD 9p21.3 not known AD With FTD not known not known
ALS 14q11.2 Angiogenin AD Classical 6 Yes
FTD (FTD3) 3 CHMP2B AD FTD (ALS) 2 not known
ALS 1 TDP43 AD ALS 14 Yes
LMND 2p13 DCTNI AD LMND 1 (+ 4 in ALS?) Yes?
AD = autosomal dominant; AR = autosomal recessive; CHMP2B = Chromatin modifying protein 2B; DCTNI = dynactin; FTD = frontotemporal 
lobe dementia; LMND = lower motor neuron disease; SETX = senataxin
VAPB = Vesicle associated membrane protein.Orphanet Journal of Rare Diseases 2009, 4:3 http://www.ojrd.com/content/4/1/3
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lower motor neuron disorder with vocal cord paralysis in
humans [89].
6. Neurofilament aggregation
Abnormal assembly with accumulation of neurofilaments
are commonly seen in several neurodegenerative condi-
tions including SALS and FALS [111,127,128]. In addi-
tion, mutations in KSP repeat region of the neurofilament
heavy (NFH) gene are found in about 1% of sporadic
cases [94,95,129]. Neurofilament proteins together with
Peripherin (an intermediate filament protein) are found
in the majority of axonal inclusions motor neurones of
ALS patients [130]. A toxic isoform of peripherin
(peripherin 61), has been found to be toxic to motor neu-
rones even when expressed at modest levels and is detect-
able in spinal cords of ALS patients but not controls [131].
7. Protein aggregation
Intra-cytoplasmic inclusions are a hallmark of both spo-
radic and familial ALS (See histopathology section). How-
ever, it is still unclear as to whether aggregate formation
directly causes cellular toxicity and have a key role in
pathogenesis, if aggregates may be innocent by-products
of the neurodegeneration process, or if formation of the
aggregates may actually be a being a beneficial process by
being part of a defence mechanism to reduce intracellular
concentrations of toxic proteins [77,78].
8. Inflammatory dysfunction and contribution of non-
neuronal cells
Although ALS is not primarily a disorder of autoimmunity
or immune dysregulation, there is considerable evidence
that inflammatory processes and non-neuronal cells may
play a part in pathogenesis of ALS. Microglial and den-
dritic cell activation is a prominent pathology in human
ALS and transgenic SOD1 mice [132-136]. These activated
non-neuronal cells produce inflammatory cytokines such
as interleukins, COX-2, TNFα and MCP-1, and evidence
of upregulation is found in CSF or spinal cord specimens
of ALS patients or in vitro models [137-140]. Despite this
evidence, immunomodulatory therapies are yet to show
promise as neuroprotective agents in clinical trials of ALS.
9. Deficits in neurotrophic factors and dysfunction of 
signalling pathways
Decreased levels of neurotrophic factors (e.g.  CTNF,
BDNF, GDNF and IGF-1) have been observed in ALS
patients post-mortem and in in vitro models [141-143]. In
addition, deletion of the hypoxia-response element in the
vascular endothelial growth factor (VEGF) gene was
found to cause a motor neurone disease in mice [144]. In
humans, three mutations in the VEGF gene were found to
be associated with increased risk of developing sporadic
ALS [99], although a recent meta-analysis by the same
authors failed to show an association between VEGF hap-
lotypes and increase the risk of ALS in humans [145].
The final process of cell death in ALS motor neurones is
thought to closely resemble a programmed cell death
pathway (apoptosis). Biochemical markers of apoptosis
are detected in the terminal stages of human and models
of ALS [146-150]. Key elements of the normal apoptotic
pathway are found to be involved in cell death in ALS,
including the caspase family of proteolytic enzymes, the
Bcl2 family of oncoproteins (anti-apoptotic and proapop-
totic oncogenes) and the apoptosis inhibitor family of
proteins (IAPs) [77,151,152].
Histopathological features
The pathological hallmarks of ALS are the degeneration
and loss of motor neurones with astrocytic gliosis and the
presence of intraneuronal inclusions in degenerating neu-
rones and glia. Upper motor neurone pathology in ALS is
indicated by depopulation of the Betz cells in the motor
cortex (Brodmann area 4), variable astrocytic gliosis
affecting both the grey matter and underlying subcortical
white matter of the motor cortex, and axonal loss within
the descending pyramidal motor pathway associated with
myelin pallor and gliosis of the corticospinal tracts
[153,154].
Lower motor neurone pathology primarily affects the ven-
tral horn motor neurones of the spinal cord and brain-
stem. There is relative sparing of the motor nucleus of
Onufrowicz in the S2 spinal segment and the cranial nerve
oculomotor nuclei [4,155]. The number of lower motor
neurones can be reduced by up to 50% at autopsy [156]
but there is considerable variation both between cases and
between different spinal levels within cases [154]. The
remaining neurones are atrophic and contain intraneuro-
nal inclusions such as:
1. Bunina bodies
These are small eosinophilic, hyaline intracytoplasmic
inclusions that stain positive for cystatin and transferring
[157,158], and are present in 70–100% of cases
[4,159,160]. Also present in Betz cells and subthalamic
nuclei. Rarely seen in other conditions.
2. Ubiquitinated inclusions or ubiquitin-immunoreactive 
(UBIs; Ub-IR)
Can be divided according to morphology into skein-like
inclusions (SLIs) which have a filamentous profile, and
more compact spherical bodies (with a rounded appear-
ance). The compact spherical bodies have also been
termed "Lewy-body like" inclusions due to the similarity
in their appearance to Lewy bodies found in Parkinson's
disease. They are almost universal in ALS and its variants,
where it can be seen in up to 95% of cases [2,3,161,162].Orphanet Journal of Rare Diseases 2009, 4:3 http://www.ojrd.com/content/4/1/3
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It has recently been found that the TAR DNA binding pro-
tein 43 (TDP-43) is the major protein constituent in the
ubiquitin positive inclusions [163-166].
3. Hyaline conglomerate (Neurofilament) inclusions 
(HCIs)
Associated with FALS and rarely seen in sporadic ALS.
These are argyrophilic inclusions seen in spinal cord
motor neurones that stain for phosphorylated and non-
phosphorylated neurofilaments [167]. They have been
also described in other neurodegenerative diseases and
normal subjects and are not as specific UBIs [168].
Contrary to early belief that ALS was a disease exclusive to
the motor system, there is now significant evidence to sug-
gest that ALS is in fact a multisystem disorder. Extra motor
pathology is found in regions such as the frontotemporal
cortex, hippocampus, thalamus [169], substantia nigra
[170], spinocerebellar pathways [171], dorsal columns
[172] and peripheral sensory nerves [173,174].
ALS variant syndromes seem to share a common molecu-
lar pathology as suggested by the findings of ubiquiti-
nated inclusions in PLS [175,176], PMA [161], Flail arm
syndrome [177,178], Flail leg [179], ALS-dementia
[180,181] and Guam ALS-PDC [182]. A recent finding is
that the TAR DNA binding protein 43 (TDP-43) has been
shown to be a major protein constituent in the ubiquitin
positive (tau and α-synuclein negative) inclusions found
in upper and lower motor neurones in ALS, frontotempo-
ral lobar degeneration with MND (FTLD-MND) and fron-
totemporal lobar degeneration with ubiquitin inclusions
(FTLD-U) [163]. TDP-43 positive inclusions were also
detected in one of two cases of PLS but appear to be neg-
ative in the inclusions seen in SOD1 positive familial ALS
[183-185].
Differential diagnosis
ALS must be differentiated from the "ALS mimic syn-
dromes" which are unrelated disorders that may have a
similar presentation and clinical features to ALS or it's var-
iants [5,74]. The most important conditions are shown in
Table 3.
Diagnostic methods
Electrophysiological studies
Patients in whom a diagnosis of ALS is suspected on clin-
ical grounds should have electrophysiological studies pri-
marily to document lower motor dysfunction in clinically
involved and uninvolved regions, and secondarily to
exclude other disease processes. The first published crite-
ria for electrodiagnosis of ALS were by Lambert in 1957
and 1969 [186,187]. The revised El-Escorial criteria [9]
have proposed electrophysiological criteria for the diag-
nosis of ALS, which have been future refined in December
2006 at an consensus conference on Awaji Island, Japan
[10]. It is important to bear in mind that clinical neuro-
physiological examination is used in the diagnosis of ALS
when the diagnosis is clinically suspected, and suggestive
neurophysiological abnormalities alone cannot clinch the
diagnosis without clinical support.
1. Nerve conduction studies (motor and sensory)
Nerve conduction studies are required for the diagnosis
principally to define and exclude other disorders of
peripheral nerve, neuromuscular junction and muscle
that may mimic or confound the diagnosis of ALS, and
these studies should generally be normal or near normal,
unless the compound muscle potential is small [9]. In
ALS, the distal motor latency (DML) and motor conduc-
tion velocity (MCV) remain almost normal, never falling
below 70% of the upper or lower limit of normal [188-
190]. Motor studies are also important in excluding multi-
focal motor neuropathy, by the detection of partial con-
duction block. A marked reduction of proximal amplitude
or negative-peak area as compared with the distal ones
(over 50%), in short segments, (excluding entrapment
sites) implies partial conduction block [191]. F-wave stud-
ies are particularly useful in assessing proximal conduc-
tion and abnormalities have been reported in ALS. These
include increased F-wave latency with normal frequency
and increased amplitude, and slowing of F-wave velocity
with decreased F-wave frequency. Prominent UMN fea-
tures may be associated with an increased F-wave fre-
quency [188].
The sensory nerve conduction studies can be abnormal in
the presence of entrapment syndromes and coexisting
peripheral nerve disease [9]. There is also recent evidence
sub-clinical involvement of the sensory system in 10–
20% of patients with ALS, suggesting an additional
polyneuropathy or sensory ganglionopathy [192,193].
2. Conventional electromyography
Concentric needle electromyography (EMG) provides evi-
dence of LMN dysfunction which is required to support a
diagnosis of ALS, and should be found in at least two of
the four CNS regions: brainstem (bulbar/cranial motor
neurons), cervical, thoracic, or lumbosacral spinal cord
(anterior horn motor neurons). For the brainstem region
it is sufficient to demonstrate EMG changes in one muscle
(e.g. tongue, facial muscles, jaw muscles). For the thoracic
spinal cord region it is sufficient to demonstrate EMG
changes either in the paraspinal muscles at or below the
T6 level or in the abdominal muscles. For the cervical and
lumbosacral spinal cord regions at least two muscles
innervated by different roots and peripheral nerves must
show EMG changes [9].Orphanet Journal of Rare Diseases 2009, 4:3 http://www.ojrd.com/content/4/1/3
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The revised El-Escorial criteria require that both evidence
of active or ongoing denervation and chronic partial den-
ervation is required for the diagnosis of ALS, although rel-
ative proportions vary from muscle to muscle [9]. Signs of
active denervation consist of:
1. fibrillation potentials
2. positive sharp waves
Signs of chronic denervation consist of:
Table 3: Diagnostic errors and most common 'ALS mimic syndromes'. (Modified from Kato et al., with permission)
Final diagnosis Characteristic features Distinguishing diagnostic features and 
investigations
Cerebral lesions Focal motor cortex lesions very rarely mimic 
ALS, but frontal lesions with co-existent 
cervical or lumbo-sacral root damage may 
cause confusion.
MRI/CT; no EMG evidence of widespread 
chronic partial denervation (CPD) in limbs
Skull base lesions Lower cranial nerve signs (bulbar symptoms 
and signs; wasting of tongue, often 
asymmetrical); seldom significant long tract 
signs unless foramen magnum involved in 
addition
MRI; CT with bone windows; no EMG evidence 
of CPD in limbs unless wasting of C8/T1 
muscles 
(rare, but present in some lesions at foramen 
magnum or high cervical level)
Cervical spondylotic myelopathy Progressive limb weakness. Asymmetrical 
onset; combined UMN and LMN signs in 
arm(s); spastic paraparesis; occasionally 
fasciculations in arms.
Pain in root distribution, but pain may not be 
severe and may resolve quickly; often 
progression followed by clinical stabilisation; no 
bulbar involvement; MRI evidence of spinal 
cord and root compression; no evidence of 
CPD on EMG (NB: patients may have co-
existent lumbo-sacral motor radiculopathy 
with lower limb denervation)
Other cervical myelopathies
￿ Foramen magnum lesions
￿ Intrinsic and extrinsic tumours
￿ Syringomyelia
Progressive weakness; foramen magnum 
lesions and high cervical cord lesions may be 
associated with focal (C8/T1) wasting; 
syringomyelia usually associated with LMN 
signs and dissociated sensory loss
Usually involvement of cerebellar and/or 
sensory pathways; MRI of head and cervical 
spine reveal pathology
Conus lesions and lumbo-sacral radiculopathy Progressive mixed UMN and LMN syndrome Usually significant sensory symptoms if not 
signs; bladder involvement; MRI thoracic and 
lumbo-sacral region; EMG evidence of 
radiculopathy
Inclusion body myositis (IBM) Progressive weakness; bulbar symptoms; 
sometimes respiratory muscle weakness
Characteristic wasting and weakness of deep 
finger flexors and quadriceps femoris; EMG 
evidence of myopathy; muscle biopsy as 
definitive test (rimmed vacuoles)
Cramp/fasciculation/myokymia syndromes Cramps, undulating muscle contractions, +/- 
weakness, stiffness 
(Isaac's syndrome; peripheral nerve hyper-
excitability syndrome)
EMG evidence of myokymia; ~30% VGKC 
antibodies; ~20% associated with thymoma or 
lung cancer; association with other 
autoimmune diseases
Multifocal motor neuropathy (MFMN) Focal asymmetrical onset, often upper limb; 
pure LMN syndrome; may stabilise for months 
or years; M:F 4:1;
Conduction block on nerve conduction studies 
(NCS); weakness often out of proportion to 
wasting; improvement with intravenous 
immunoglobulin (IVIG) in ~70%
Kennedy's disease 
(X-linked bulbar and spinal muscular atrophy)
Males symptomatic; slowly progressive bulbar 
and limb weakness
Family history; fasciculations of facial muscles; 
gynaecomastia; proximal symmetrical weakness 
in addition to foot drop; mild sensory 
neuropathy on NCS; positive DNA test for 
CAG repeat mutation in exon 1 of androgen 
receptor geneOrphanet Journal of Rare Diseases 2009, 4:3 http://www.ojrd.com/content/4/1/3
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1. large motor unit potentials of increased duration with
an increased proportion of polyphasic potentials, often of
increased amplitude
2. reduced interference pattern with firing rates higher
than 10 Hz (unless there is a significant UMN component,
in which case the firing rate may be lower than 10 Hz)
3. unstable motor unit potentials.
Fasciculation potentials are an important characteristic
finding in ALS, although they can be seen in normal mus-
cles (benign fasciculations) and are not present in all mus-
cles in ALS patients. In benign fasciculations the
morphology of the fasciculation potentials are normal,
whereas in fasciculation potentials associated with neuro-
genic change there are abnormal and complex morphol-
ogy [10,194]. The Awaji group suggest that the presence of
abnormal complex fasciculation potentials in a muscle
showing neurogenic change, can be considered equivalent
in importance to fibrillation potentials or positive sharp
waves [10].
3. Transcranial magnetic stimulation and Central motor conduction 
studies
Transcranial magnetic stimulation (TMS) allows a non-
invasive evaluation of corticospinal motor pathways, and
allows detection of UMN lesions in patients who lack
UMN signs. Motor amplitude, cortical threshold, central
motor conduction time and silent periods can be easily
evaluated using this method [195]. Central motor con-
duction time (CMCT) is often marginally prolonged to
muscles of at least one extremity in ALS patients. Electro-
physiological features compatible with UMN involve-
ment include [9]:
1. Up to a 30% increase in central motor conduction time
determined by cortical magnetic stimulation and
2. Low firing rates of motor unit potentials on maximal
effort.
Marked prolongation in the CMCT is seen in FALS
patients with D90A SOD1 mutations and patients with
the flail arm and flail leg variants [196-198].
4. Quantitative electromyography
Motor unit number estimation (MUNE) is a special elec-
trophysiological technique that can provide a quantitative
estimate of the number of axons innervating a muscle or
group of muscles. MUNE consists of a number of different
methods (incremental, multiple point stimulation, spike-
triggered averaging, F-wave, and statistical methods), with
each having specific advantages and limitations. Despite
the lack of a perfect single method for performing MUNE,
it may have value in the assessment of progressive motor
axon loss in ALS, and may have use as an end-point meas-
ure in clinical trials [199].
Neuroimaging studies
The most important use of neuroimaging is in the diagno-
sis of ALS to exclude treatable structural lesion that mim-
ics ALS by producing varying degrees of UMN and LMN
signs, especially in those with clinically probable or possi-
ble ALS. The WFN revised criteria state that imaging stud-
ies are not required in cases that have clinically definite
disease with bulbar or pseudobulbar onset as it is unlikely
that structural lesions can mimic clinically definite disease
[9]. Magnetic resonance imaging (MRI) can be used in
revealing lesions in the corticospinal tracts in ALS. The
most characteristic finding in ALS is hyperintensity of the
corticospinal tracts on T2-weighted, proton density
weighted and FLAIR-weighted MRI, and is best visualised
in the brain and brainstem and to a lesser extent in the spi-
nal cord [200-203]. T2 weighted MRI may also show
hypointensity of the primary motor cortex, usually along
the posterior bank of the precentral gyrus, although this is
an inconsistent and non-specific finding [204].
More advanced neuroimaging modalities such as mag-
netic resonance spectroscopy, diffusion weighted imaging
(DWI)/diffusion tensor imaging (DTI), magnetic reso-
nance voxel-based morphometry and functional imaging
techniques (fMRI, PET and SPECT) have a limited role in
routine clinical practice but have shown promise in
understanding pathophysiology of the disease in vivo,
identification of potential biomarkers of disease progres-
sion and identifying disease changes earlier in the course
of the disease facilitating earlier diagnosis [205-210].
Muscle biopsy and neuropathalogical studies
Biopsy of skeletal muscle or other tissues is not required
for diagnosis, unless to rule out a mimic syndrome (e.g.
Inclusion body myositis). In addition, muscle biopsy may
be used to demonstrate LMN dysfunction in a body region
when clinical or electrophysiological findings do not sup-
port this. Histological findings that are compatible with
the diagnosis of ALS include [9]:
￿ Scattered hypertrophied muscle fibres.
￿ No more than a moderate number of target or targetoid
fibres.
￿ Fibre type grouping of no more than mild-to-moderate
extent.
￿ The presence of a small number of necrotic muscle
fibres.Orphanet Journal of Rare Diseases 2009, 4:3 http://www.ojrd.com/content/4/1/3
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Other laboratory studies
There are few other investigations that may be considered
mandatory in the work-up of an ALS patient. Clinical lab-
oratory tests that may be abnormal in otherwise typical
case of ALS include [9]:
￿ Muscle enzymes (serum creatine kinase [unusual above
ten times upper limit of normal], ALT, AST, LDH)
￿ Serum creatinine (related to loss of skeletal muscle
mass)
￿ Hypochloremia, increased bicarbonate (related to
advanced respiratory compromise)
￿ Elevated CSF protein (uncommonly more than 100 mg/
dl)
Management
The management of ALS/MND has considerably changed
over the past two decades, with a emphasis on coordi-
nated multidisciplinary care between specialist, commu-
nity based therapists and palliative care teams. Although
the condition is considered incurable, many of the symp-
toms arising during the course of the disease are treatable,
and all efforts should be made to improve quality of life
and help maintain the patient's autonomy for as long as
possible. Advanced directives on end of life care, respira-
tory and nutritional management during late stages of life
are important issues, and should be discussed with
patients and relatives at the earliest opportunity that they
are willing to do this. Patients with ALS and their relatives
are likely to suffer from depression, feelings of hopeless-
ness and anxiety regarding end-of-life issues following the
diagnosis or as the disease progresses [211,212]. There-
fore, psychological support in the form of counselling and
palliative care should be offered to the patients and rela-
tives early [74,213].
Symptomatic treatments
Symptomatic treatments aim to improve quality of life of
patients and care givers. The main symptoms encountered
in ALS and their management are shown in Table 4.
Ventilatory management
Respiratory insufficiency occurs commonly in patients
with ALS and is a major cause of mortality. The presenting
symptoms of respiratory muscle weakness include dysp-
noea on exertion or talking, orthopneoa, disturbed sleep,
excessive daytime somnolence, morning headaches,
fatigue, anorexia, depression, poor concentration, vivid
nightmares and nocturia. Clinical signs evident on exam-
ination include tachypnoea, use of accessory breathing
muscles, paradoxical movement of the abdomen, weak
cough and rarely papilloedema [74,214].
Measurements of the forced vital capacity (FVC) or
relaxed (slow) vital capacity (SVC) are the most widely
available measures for detecting respiratory decline. Meas-
urement of the Sniff nasal inspiratory pressure (SNIP) is a
good measure of diaphragmatic strength and is probably
more accurate than vital capacity, although both measure-
ments underestimate respiratory function in patients with
bulbar impairment. The American Academy of Neurology
(AAN) ALS Practice Parameter (1999) recommends start-
ing non-invasive ventilation when forced vital capacity
declines to 50% of the predicted value [215]. However,
patients can develop respiratory failure with a forced vital
capacity above 70% of the predicted value, therefore a
forced vital capacity of 75% or less is probably more
appropriate as a threshold for closer monitoring of respi-
ratory symptoms [216-218]. A SNIP of 32% (~25 cms
H2O) or less is highly predictive of respiratory failure
[219]. Overnight oximetry can reveal episodes of desatu-
ration consistent with nocturnal hypoventilation. Abnor-
malities of arterial or venous (ear lobe) blood gases, such
as respiratory acidosis are a late but important finding that
signifies the need for respiratory support.
Respiratory support is usually provided by non-invasive
ventilation (NIV) or invasive ventilation via tracheotomy.
Bi-level positive pressure devices (BiPAP) are the com-
monly used form of NIV, whereas continuous positive
pressure (CPAP) ventilation is not usually helpful [220].
The timing of initiating NIV treatment varies between
counties and centres, but most published international
guidelines such as those by the EALSC's work shop group
[221] and EFNS task force [222], suggest the criteria pro-
posed by the European ALS/MND Consortium and Euro-
pean Neuromuscular Centre workshop on non-invasive
ventilation in MND in May 2002, and are shown in Table
5[74].
NIV is usually initially used for intermittent nocturnal
support to alleviate symptoms of nocturnal hypoventila-
tion, although as respiratory function worsens, patients
tend to require increasing daytime support and eventually
continuous support. Observational studies and a recent
randomised controlled trial involving 92 ALS patients
show that NIV improves survival and quality of life
[223,224]. In patients with severe bulbar impairment,
NIV improves sleep-related symptoms, but is unlikely to
confer a large survival advantage [223].
Nutritional management
Dysphagia is a common symptom of ALS and leads to
increased risk of aspiration, malnutrition, weight loss and
dehydration. Malnutrition and dehydration can also
occur inpatients whom have severe upper limb weakness,
especially if they live alone, as this leads to difficulties in
meal preparation or prolonged meal times. ALS is associ-Orphanet Journal of Rare Diseases 2009, 4:3 http://www.ojrd.com/content/4/1/3
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Table 4: Symptomatic treatments for ALS (with permission from Radunović et al. 2007)
Drugs Other treatments
Cramps ￿ Carbamazepine ￿ Physiotherapy
￿ Phenytoin ￿ Physical exercise
￿ Quinine (removed from US market) ￿ Massage
￿ Hydrotherapy
Spasticity ￿ Baclofen ￿ Physiotherapy
￿ Tizanidine ￿ Hydrotherapy
￿ Dantrolene ￿ Cryotherapy
￿ Botulinum toxin type A
Excessive watery saliva ￿ Atropine ￿ Home suction device
￿ Hyoscine hydrobromide ￿ Dark grape juice
￿ Hyoscine butylbromide ￿ Sugar-free citrus lozenges
￿ Hyoscine scopoderm ￿ Nebulisation
￿ Glycopyrronium ￿ Steam inhalation
￿ Amitriptyline ￿ Injections of botulinum toxin into parotid glands
￿ Irradiation of the salivary glands
Persistent saliva and bronchial secretions ￿ Carbocisteine ￿ Home suction device
￿ Propranolol ￿ Assisted cough insufflator-exsufflator
￿ Metoprolol ￿ Rehydration (jelly or ice)
￿ Pineapple or papaya juice
￿ Reduced intake of diary products, alcohol, and caffeine
Excessive or violent yawning Baclofen
Laryngospasm Lorazepam Reassurance
Pain ￿ Simple analgesics Comfort (seating, sleeping, day and night care)
￿ Non-steroidal anti-inflammatory drugs
￿ Opioids
Emotional lability ￿ Tricyclic antidepressant
￿ Selective serotonin-reuptake inhibitors
￿ Levodopa
￿ Dextrometorphan and quinidine
Communication difficulties ￿ Speaking techniques
￿ Low-tech augmentative and alternative communication 
tools
￿ Voice amplifiers
￿ Light writers
￿ Scanning systems operated by switches
￿ Brain-computer interfaces
Constipation ￿ Lactulose ￿ Hydration
￿ Senna ￿ Increased fibre intake
Depression ￿ Amitriptyline ￿ Psychological support, counselling
￿ Citalopram
Insomnia ￿ Amitriptyline Comfort, analgesia
￿ Zolpidem
Anxiety Lorazepam Psychological support, counselling
Fatigue ModafinilOrphanet Journal of Rare Diseases 2009, 4:3 http://www.ojrd.com/content/4/1/3
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ated with a hyper metabolic state, therefore patients
require increased calorie intake [225,226]. Early manage-
ment of dysphagia includes dietary advice, modification
of food consistency (blending solid, adding thickening
agents to liquids) and educating patients on special swal-
lowing techniques (such as supraglottic swallowing and
postural changes ('Chin tuck manoeuvre') [74,222].
Most guidelines state that supplementary enteral feeding
should be considered when body weight falls by > 10% of
the pre-diagnostic or baseline weight [74,222]. The three
options available for enteric feeding include percutaneous
endoscopic gastrostomy (PEG), percutaneous radiologic
gastrostomy (PRG) or radiologically inserted gastrostomy
(RIG), and nasogastric tube (NGT) feeding. PEG is the
standard procedure for enteral feeding, although the pro-
cedure requires mild sedation and therefore has implica-
tions in patients with respiratory weakness. To minimise
risks, evidence suggests that PEG should be performed
before VC falls below 50% of predicted [74,227].
Although it may be possible to insert PEG with NIV assist-
ance, PRG/RIG insertion is a better alternative in these
patients [228-230]. NGT is a relatively non-invasive
option, but is limited by discomfort and problems associ-
ated with long term use such as frequent replacement, and
should only be considered in patients who cannot
undergo PEG or RIG insertion.
Disease modifying treatments
Despite many clinical trials and various advances in the
understanding of ALS, there has been little success in the
search for disease modifying or neuroprotective agents.
Riluzole is the only approved drug that has been shown to
have a modest effect on prolonging life in ALS patients
[231-237]. The mechanism of action of riluzole is not
entirely certain but is though to include interference with
N-methyl-D-aspartate (NMDA) receptor mediated
responses, stabilisation of the inactivated state of voltage-
dependent sodium channels, inhibition of glutamate
release from pre-synaptic terminals, and increasing of
extracellular glutamate uptake [238]. The conclusion of a
recent Cochrane Collaboration meta-analysis stated that
riluzole at 100 mg probably prolongs median survival by
2–3 months when taken for a 18 month duration (in
patients clinically probable or definite El Escorial ALS,
with symptoms less than 5 years, FVC > 60% and age < 75
years) [239]. The absolute risk reduction with the 100 mg
dose at 12 months was 9%, with the numbers needed-to-
treat to delay one death (NNT) after 12 months is 11
[239]. The drug is generally well tolerated with the most
common side effects being asthenia, nausea, gastrointesti-
nal upset and abnormal liver function tests, and therefore
liver function should be regularly monitored during ther-
apy [240].
Over 100 other neuroprotective agents have been studied
in animal models and humans. Some agents that have
been evaluated in phase II or III human clinical trials and
have shown inconclusive evidence or failed to demon-
strate effectiveness for routine clinical practice include:
￿ Subcutaneous recombinant human insulin-like growth
factor (IGF-1, ormyotrophin), neurotrophins including
brain derived neurotrophic factor, ciliary neurotrophic
factor, glial cell line derived neurotrophic factor and oral
xaliproden [241-245]
￿ Ceftriaxone [246]
￿ Talampanel (8-methyl-7H-1,3-dioxolo(2,3)benzodi-
azepine)
Table 5: Suggested criteria for non-invasive ventilation (NIV): Provisional European consensus criteria for NIV (European ALS/MND 
Consortium and European Neuromuscular Centre workshop on non-invasive ventilation in MND, May 2002) [with permission from 
Leigh et al. 2003]
Symptoms related to respiratory muscle weakness. At least one of
￿ Dyspnoea
￿ Orthopnoea
￿ Disturbed sleep (not caused by pain)
￿ Morning headache
￿ Poor concentration
￿ Anorexia
￿ Excessive daytime sleepiness (ESS > 9)
AND Evidence of respiratory muscle weakness (FVC ≤ 80% or SNP ≤ 40 cmH2O)
AND Evidence of EITHER:
significant nocturnal desaturation on overnight oximetry
OR
morning ear lobe blood gas pCO2 ≥ 6.5 kPa
ESS, Epworth sleepiness scaleOrphanet Journal of Rare Diseases 2009, 4:3 http://www.ojrd.com/content/4/1/3
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￿ Tamoxifen [247]
￿ Minocycline [248]
￿ TCH346 [249]
￿ Coenzyme Q10 [250]
￿ Vitamin E [251,252]
￿ Celecoxib [253]
￿ Creatine [254,255]
￿ Copaxone [256]
￿ ONO 2506 – A randomised placebo-controlled investi-
gate efficacy and safety of ONO-2506PO in the presence
of riluzole was negative overall in 2004 but showed a
trend towards improved survival in those who started the
drug within 14 months of onset.
The use of gene therapy approach to deliver neurotrophic
factors directly to neurons by means of genetically engi-
neered adeno-associated viruses (AAV) expressing neuro-
trophic factor genes has been evaluated in SOD1 mouse
models with some promising results [257], but human
studies are not yet underway. Another approach is the use
of autologous stem cell transplantation, but to date there
have been no convincing results from human studies
[258,259]. The recent discovery of the ability to re-pro-
gramme human skin fibroblast generate pluripotent stem
cells (Induced pluripotent stem cells; iPS) [260] would
allow patient and disease specific stem cells to produced,
leading to better disease models and eventually better
autologous cell replacement therapies.
Prognosis
Analysis of large patient samples drawn from clinic based
populations or population registries consistently show
that the overall median survival from onset of symptoms
for ALS ranges between 2–3 years for bulbar onset cases
and 3–5 years for limb onset ALS cases [12,58,261]. Large
clinic cohort studies have shown 3 year and 5 year survival
tares to be around 48% and 24% respectively, with
approximately 4% surviving longer than 10 years
[262,263], whereas 5 year survival reported in population
based studies is much lower and ranges from 4–30% [12].
Important prognostic indicators of survival consistently
arising from population based studies and clinic cohort
studies include clinical phenotype (PMA and Flail arm
have better prognosis than typical forms) [264], site of
onset (bulbar vs. limb onset) [17,261,264-266], age of
symptom onset [58,261,264-267], shorter time from
symptom onset to diagnosis [266], baseline FVC decline
[261,265,268], El Escorial category at presentation
[17,267] and riluzole use [265,269].
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Appendix 1 – Some exogenous risk factors 
implicated in sporadic ALS
￿ Age at menopause (females) [270,271]Orphanet Journal of Rare Diseases 2009, 4:3 http://www.ojrd.com/content/4/1/3
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￿ Dietary factors [272]
￿ Electrical injury [273]
￿ Family history of non-ALS neurodegenerative disease
(Parkinson's or Alzheimer's disease) [274]
￿ Geographical residence (rural, suburban or urban) [275]
￿ Gulf war service (Male veterans) [276-278]
￿ Maternal age [279], Number of births (in females) &
Birth order [81,279,280], Loss of child [281]
￿ Occupation [81,282]
￿ Physical activity [283,284],
￿ Playing football professionally [285-287]
￿ Previous poliomyelitis infection [288]
￿ Race/ethnicity [289]
￿ Smoking [79-81,290,291]
￿ Toxin exposure (agricultural chemicals, lead) [282,292]
￿ Trauma (e.g. Head injury) [274,285,293]
￿ Years of education [81]
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